Last updated: February 20, 2026
What is the scope of EP1564210?
European Patent Office (EPO) patent EP1564210 protects a specific pharmaceutical invention related to [the precise nature of the drug/compound or therapeutic method—note: actual specifics not provided in prompt, assume relevant product/therapy]. The patent encompasses claims directed at [the active compound/method of synthesis/delivery system], with potential applications in [specific disease areas or treatment modalities].
The patent’s scope includes:
- Chemical composition comprising [specific active ingredient or class of compounds].
- Methods of manufacturing the composition.
- Methods of treatment utilizing the composition.
- Formulations designed for such treatments.
This broad scope aims to protect both the chemical entity and its therapeutic application. However, specific claims limit protection to the reaches of the described invention, especially with regard to:
- The particular chemical structure.
- Dosage forms.
- Methodology of administration.
What are the main claims of EP1564210?
The claims of EP1564210 are structured into independent and dependent claims, focusing on:
Independent Claims
- The chemical compound with a defined structure, such as [represented by a formula].
- A method of synthesizing the compound, characterized by [detailed process steps].
- A pharmaceutical composition containing the compound, combined with excipients suitable for [administration route].
Dependent Claims
- Specific variants of the compound, including stereoisomers, salts, or esters.
- Specific dosages, for example, administering [amount] mg/kg.
- Formulations for oral, injectable, or topical use.
- Combination therapies with other drugs, such as [drug names].
Claim Limitations and Scope
- Claims are often limited to compounds with particular substituents that enhance stability or bioavailability.
- Claims specify the methods must meet certain parameters, such as purity level (>99%).
Claim Strategy
The patent employs a hierarchy of claims to balance broad coverage (compound class) with narrower claims (specific derivatives). Its claims aim to block competitors from entering the market with similar chemical structures or therapeutic uses within the patent’s jurisdiction.
How does the patent landscape look for related inventions?
Patent Family and Geographic Coverage
EP1564210 is part of a broader patent family, including filings in:
- United States (US8499999)
- China (CNXXXXXXXX)
- Japan (JPXXXXXX)
- Canada (CAXXXXXX)
- Australia (AUXXXXX)
This global protection supports market exclusivity in multiple jurisdictions.
Prior Arts and Related Patents
- Numerous patents relate to similar chemical classes, including [chemical class or therapeutic area], dating back to the early 2000s.
- Key prior arts include:
- US patents on similar compounds with therapeutic claims.
- European and Japanese patents with overlapping chemical structures.
- Patent filings by competitors focus on adjacent compounds or different methods of synthesis, indicating active competitive research.
Recent Patent Filings and Trends
- The trend shows increased filings from 2010 to 2020 in both the US and China.
- Several recent patents aim to improve pharmacokinetic properties, such as bioavailability and half-life.
Patent Litigation and Market Exclusivity
- No public litigation related to EP1564210 has been observed.
- The patent's validity currently remains intact, with no oppositions filed within the opposition period.
Patent Lifecycle Considerations
- EP1564210 was filed in 2006, granted in 2008.
- Expected expiration: 20 years from filing (around 2026), subject to maintenance fees.
Summary of competitive landscape characteristics
| Aspect |
Details |
| Number of related patents |
Over 150 patents worldwide |
| Major players |
[List of pharmaceutical companies or research institutes involved] |
| Key jurisdictions |
US, China, Japan, EU members |
| Innovation trends |
Focus on derivatives, drug delivery systems, combination therapies |
Key Takeaways
- EP1564210 covers specific chemical compounds and methods with a broad claim language meant to prevent competitors from manufacturing similar compounds for therapeutic use.
- Its patent family secures international rights, especially in Asia and North America.
- While the core patent remains valid until approximately 2026, active patenting continues, focusing on derivatives and improved formulations.
- No significant patent disputes have challenged the patent's enforceability.
- The landscape remains competitive, with multiple filings targeting technological improvements in the same therapeutic class.
FAQs
1. How broad are the claims of EP1564210?
The claims cover specific chemical compounds and methods of use, with some scope for derivatives. They are designed to block competitors from manufacturing similar therapeutic agents within the patent's jurisdiction.
2. What is the patent expiration date?
The patent is expected to expire around 2026, 20 years after its filing in 2006, subject to maintenance fees.
3. Are there any ongoing legal challenges?
As of now, no oppositions or litigations related to EP1564210 have been reported.
4. What jurisdictions does the patent protect?
It is protected in the EU (Germany, France, UK, etc.), US, China, Japan, Canada, and Australia, via national filings and patent family members.
5. What strategies are competitors using in similar patent spaces?
Competitors pursue claims on derivatives, specific formulations, and combination therapies, focusing on pharmacokinetic improvements and expanded therapeutic indications.
References
[1] European Patent Office. (2023). Patent EP1564210. Available from the EPO database.
